Mirador Therapeutics

Thank you to San Diego Mayor Todd Gloria for attending the grand opening celebration of Mirador's new headquarters yesterday! We're thrilled to open the doors to our state-of-the-art home that empowers our mission to transform lives through innovative precision medicine for immune-mediated disease.

Our Chairman and CEO Mark McKenna and Tim Ingrassia of Goldman Sachs will be participating in a fireside chat on Tuesday, February 25 at 1:30 p.m. PT at Biocom California’s Global Life Science Partnering & Investor Conference. During the #BiocomGPIC event, industry leaders have the opportunity to debate current trends and showcase their latest innovations. Learn more about the conference here: https://lnkd.in/gzh_eCPV

"Getting treatments to patients as fast as we can is going to change lives." Our founder and CEO Mark McKenna sat down with Dan Dees to discuss the importance of strong leadership and building a meaningful network as an entrepreneur in #biotech. They also speak to the value of taking business risks to treat patients faster and #AI's role in making it happen. Watch the full interview here: https://lnkd.in/es7XwnB9

Heading to #JPM25? Our Founder, Chairman and CEO Mark McKenna will participate in a panel at the Endpoints News event on Monday, January 13. He will join a group of other industry leaders to discuss what's on the horizon for dealmaking in 2025 in reference to the new administration and a changing economic environment. Hear Mark's outlook by tuning into the event, and see the full agenda here: https://lnkd.in/eYyFKKbD

We're pleased to be part of the BioSpace NextGen Class of 2025, a list of new companies making an impact in the #biotech space. Mirador aims to revolutionize #precisionmedicine with our proprietary Mirador360™ development engine that leverages cutting-edge biology, multi-modal data and advanced analytics to rapidly advance new medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. We're thankful to BioSpace for recognizing our progress and the potential impact our science can have on patients and the broader life sciences community. https://lnkd.in/eVKpgZix

Today we announced an exciting new strategic research collaboration with Mirador Therapeutics, which will leverage 23andMe’s research database to advance Mirador’s precision medicines for immunology and inflammation! 🎉 Read more: https://23and.me/mirador

We're excited to announce that we have been honored with the 2025 BioSpace Best Places to Work Award! This recognition is a testament to the exceptional culture and unwavering commitment our team has to revolutionizing the future of #precisionmedicine for patients living with immune-mediated inflammatory and fibrotic diseases. Thank you to each member of the Mirador team for making our company a dynamic and inspiring place to work every single day.

We're honored to be named a 2024 Endpoints 11 award winner. At Mirador, we envision a bold new era of #precisionmedicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy. We're extending our gratitude to the entire Mirador team, investors, physicians and patients who make our work possible. In addition, thank you to John Carroll and the Endpoints News team for including us on this prestigious list and acknowledging our potential to improve lives through innovative I&I precision medicines. https://lnkd.in/et3jc_vr

Our Chairman and CEO Mark McKenna will participate in a fireside chat at the World Medical Innovation Forum, presented by Mass General Brigham and Bank of America. We're looking forward to sharing more about our bold and visionary approach.